Circulating Factors in Nephrotic Syndrome

ConditionsNephrotic Syndrome Membranous Nephropathy Minimal Change Disease Primary Focal Segmental Glomerulosclerosis

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorIain Bressendorff

About this trial

A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

Plasma albumin < 36 g/L

Urine protein >3.5 g/day or urine protein/creatinine-ratio (UPCR) > 3.5 or urine albumin/creatinine-ratio (UACR) >2200 mg/g

Planned kidney biopsy

Disqualifiers

Kidney transplant recipient

Previously undergone a kidney biopsy

Unable to understand written information in Danish

Trial population

De novo nephrotic syndrome admitted to hospital for a clinically indicated kidney biopsy.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Observation
Other intervention
Observation

Treatment groups

104 Participants

are divided into 1 treatment group

Group A: Patients with de novo nephrotic syndrome1 intervention

Trial outcomes

Primary outcomes

levels of anti-nephrin in blood by ELISA

temporal association of anti-nephrin with clinical remission of nephrotic syndrome

Time frame

up to 12 months

Secondary outcomes

changes in auto-antibodies in blood associated with membranous nephropathy

temporal association of auto-antibodies with clinical remission of nephrotic syndrome

Time frame

up to 24 months

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Iain Bressendorff

Lead sponsor

Herlev Hospital

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: